On improving research methodology in clinical trials

Statistical Methods in Medical Research

Volumn 17, Issue 3, 2008, Pages 231-242

  Berger, Vance W ^a,d   Matthews, J Rosser ^b   Grosch, Eric N ^c  

^a UNIVERSITY OF MARYLAND   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c United Urgent Care Clinic   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; EVIDENCE BASED MEDICINE; MEDICAL DECISION MAKING; MEDICAL PRACTICE; METHODOLOGY; MULTIMETHOD STUDY; NATURAL SELECTION; OUTCOME ASSESSMENT; PATIENT SAFETY; STANDARDIZATION; STATISTICAL ANALYSIS; SYSTEMATIC ERROR;

BIOMETRY; CLINICAL TRIALS AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH;

EID: 48049083740     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1177/0962280207080639     Document Type: Article

References (21)

1. Hart HG. On authorship and acknowledgements. New England Journal of Medicine 1992; 326(16): 1084. ISI. 1985. http://isi.cbs.n1/ ethics.htm. Accessed 27 February 2006.
2. Berger VW. On the generation and ownership of alpha in medical studies. Controlled Clinical Trials 2004; 25(6): 613-19.
3. Feigenbaum S, Levy DM. The technological obsolescence of scientific fraud. Rationality and Society 1996; 8: 261-76.
4. Berger VW, Durkalski VL. Analysis of trichotomous pharmaceutical endpoints. Journal of Biopharmaceutical Statistics 2005; 15: 739-45.
5. Altman DG. Poor-quality medical research. What can journals do? JAMA 2002; 287(21): 2765-67.
6. Rawls J. A theory of justice. Harvard University Press, 1971.
7. Frankena WK. Ethics. Prentice Hall, Inc., 1963.
8. Moyé LA, Abernethy B, von Olshausen K, Pop T et al. Carvedilot in patients with chronic heart failure. The New England Journal of Medicine 1996; 335: 1318-20.
9. Berger VW, Rezvani A, Markarewicz V. Direct effect on validity of response run-in selection in clinical trials. Controlled Clinical Trials 2003; 24(2): 156-66.
10. Berger VW, Ivanova A, Deloria-Knoll M. Minimizing predictability while retaining balance through the use of less restrictive randomization procedures. Statistics in Medicine 2003; 22(19): 3017-28.
11. Berger VW. Selection bias and covariate imbalances in randomized clinical trials. Chichester: John Wiley & Sons, 2005A.
12. Berger VW. Is allocation concealment a binary phenomenon? Medical Journal of Australia 2005b; 183(3):165.
13. Mitchell JRA. Timolol after myocardial infarction: an answer or a new set of questions? Br Med J (Clin Res Ed) 1981; 282: 1565-70.
14. Lindholm L, Ibsen H, Dahlöf B, Devereux R, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen S, Kristiansson K. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet 2002; 359: 1004-10.
15. Sleight P, Pogue J, Yusuf S. Blood pressure and cardiovascular risk in the HOPE study. The Lancet 2001; 359: 2118.
16. Berger VW, Exner DV. Detecting selection bias in randomized clinical trials. Controlled Clinical Trials 1999; 20(4): 319-27.
17. Berger VW. The reverse propensity score to manage baseline imbalances in randomized trials. Statistics in Medicine 2005C; 24: 2777-87.
18. Berger VW. Pros and cons of permutation tests in clinical trials. Statistics in Medicine 2000; 19: 1319-28.
19. Chassin MR, Brook RH, Park RE et al. Variations in the use of medical and surgical services by the medicare population. NEJM 314: 285-90.
20. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T. The Revised CONSORT Statement for reporting randomized trials: explanation and elaboration. Annals of Internal Medicine 2001; 134(8): 663-94.
21. Lewis JA. Statistical principles for clinical trials (ICH E9) an introductory note on an international guideline. Statistics in Medicine 1999; 18(15): 1903-04.